Is there a generic version of sotolaxib available in India? How much does it cost?

Sotorasib is a new type of anti-cancer drug that belongs to the category of targeted therapy drugs. Its development marks a breakthrough for the KRAS G12C mutation, which has long been considered difficult to treat and is common in many cancers, especially non-small cell lung cancer (NSCLC).

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive.

The cheaper ones are the generic drugs sold abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan, which is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs. There are currently no generic drugs officially on the market in India, mainly generic drugs from Bangladesh and Laos.

KRAS G12C mutation leads to abnormal activation of intracellular signaling pathways, thereby promoting uncontrolled proliferation and survival of cancer cells. Sotoracib specifically binds to the KRAS G12C mutation and inhibits its activity, thereby interfering with abnormal signaling and inhibiting the growth and spread of cancer cells.

The development of this drug represents an important advance in the field of cancer treatment for the precise treatment of specific genetic mutations. What's special about sotoraxib is that it targets KRAS G12C, a cancer-causing mutation that has long been considered difficult to intervene. The launch of the drug provides a new treatment option for cancer patients with KRAS G12C mutations, especially when traditional treatments cannot meet their needs.

Sotorasiib is an oral medication that patients usually need to take at the prescribed dosage under the supervision and advice of their doctor. Before use, doctors usually conduct genetic testing to determine whether the patient carries the KRAS G12C mutation to confirm whether the drug is suitable for use.